z-logo
open-access-imgOpen Access
Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia
Author(s) -
Christopher M. Jones,
Ashwini Mallappa,
Nicole Reisch,
Nikolaos Nikolaou,
Nils Krone,
Beverly Hughes,
Donna O’Neil,
Martin J. Whitaker,
Jeremy Tomlinson,
KarlHeinz Storbeck,
Deborah P. Merke,
Richard Ross,
Wiebke Arlt
Publication year - 2016
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2016-2855
Subject(s) - androstenedione , congenital adrenal hyperplasia , endocrinology , androgen , dehydroepiandrosterone , medicine , context (archaeology) , glucocorticoid , dihydrotestosterone , testosterone (patch) , androgen excess , chemistry , hormone , biology , paleontology , insulin resistance , polycystic ovary , insulin
The classic androgen synthesis pathway proceeds via dehydroepiandrosterone, androstenedione, and testosterone to 5α-dihydrotestosterone. However, 5α-dihydrotestosterone synthesis can also be achieved by an alternative pathway originating from 17α-hydroxyprogesterone (17OHP), which accumulates in congenital adrenal hyperplasia (CAH). Similarly, recent work has highlighted androstenedione-derived 11-oxygenated 19-carbon steroids as active androgens, and in CAH, androstenedione is generated directly from 17OHP. The exact contribution of alternative pathway activity to androgen excess in CAH and its response to glucocorticoid (GC) therapy is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom